INmune Bio (INMB) News Today $7.64 -0.12 (-1.55%) As of 01:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8thMay 5 at 7:00 AM | globenewswire.comRenaissance Technologies LLC Increases Position in INmune Bio, Inc. (NASDAQ:INMB)Renaissance Technologies LLC lifted its holdings in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 73.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,800 shares of the company's stock after acquiring an addMay 4 at 3:27 AM | marketbeat.comAnalysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80May 4 at 1:57 AM | americanbankingnews.com475,551 Shares in INmune Bio, Inc. (NASDAQ:INMB) Acquired by Raymond James Financial Inc.Raymond James Financial Inc. bought a new position in INmune Bio, Inc. (NASDAQ:INMB - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 475,551 shares of the company's stock, valued at approximately $2,221,000. Raymond JMay 3 at 3:38 AM | marketbeat.comINmune Bio (INMB) Expected to Announce Quarterly Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-inmune-bio-inc-stock/)May 3 at 2:46 AM | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Buy" by BrokeragesShares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been assigned a consensus rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendatMay 1, 2025 | marketbeat.comWalleye Capital LLC Acquires New Shares in INmune Bio, Inc. (NASDAQ:INMB)Walleye Capital LLC bought a new position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 33,719 shares of the company's stock, valued at apprApril 29, 2025 | marketbeat.comDauntless Investment Group LLC Makes New $896,000 Investment in INmune Bio, Inc. (NASDAQ:INMB)Dauntless Investment Group LLC purchased a new position in INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 191,822 shares of the company's stock, valued at approApril 26, 2025 | marketbeat.comINmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform TechnologyApril 16, 2025 | markets.businessinsider.comINmune Bio receives favorable patentability opinion for CORDStrom platformApril 16, 2025 | markets.businessinsider.comINmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStromApril 14, 2025 | markets.businessinsider.comINmune Bio Partners with Cell and Gene Therapy CatapultApril 14, 2025 | msn.comINmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial ReadinessApril 14, 2025 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by BrokeragesShares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to theApril 6, 2025 | marketbeat.comINmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II StudyApril 1, 2025 | markets.businessinsider.comRaymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB)Raymond James Financial Inc. purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 475,551 shares of the company's stock, valued at approximately $March 31, 2025 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comINmune Bio (NASDAQ:INMB) Posts Earnings ResultsINmune Bio (NASDAQ:INMB - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.14.March 29, 2025 | marketbeat.comINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business UpdateMarch 29, 2025 | finanznachrichten.deScotiabank Remains a Buy on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comAlliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comINmune Bio, Inc. (INMB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comINmune Bio Inc. Announces Year End 2024 Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.comWhat to Expect from INmune Bio's EarningsMarch 27, 2025 | benzinga.comINmune Bio (INMB) Projected to Post Quarterly Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comINmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's ResultsMarch 18, 2025 | seekingalpha.comINmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by AnalystsShares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toMarch 10, 2025 | marketbeat.comELEVAI Labs Inc. Ends License Agreement with INmuneMarch 3, 2025 | tipranks.comINmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%February 20, 2025 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Short Interest UpdateINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 5,510,000 shares, an increase of 9.5% from the January 15th total of 5,030,000 shares. Based on an average daily volume of 330,500 shares, the days-to-cover ratio is presently 16.7 days.February 17, 2025 | marketbeat.comINmune Bio (NASDAQ:INMB) Given New $30.00 Price Target at Maxim GroupMaxim Group boosted their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday.February 14, 2025 | marketbeat.comINmune Bio price target raised to $30 from $22 at MaximFebruary 13, 2025 | markets.businessinsider.comINmune Bio, Inc.: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate CancerFebruary 13, 2025 | finanznachrichten.deRaymond James raises INmune Bio stock target to $23February 12, 2025 | msn.comINmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate CancerFebruary 12, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)February 11, 2025 | markets.businessinsider.comScotiabank raises INmune Bio stock target to $23 on new therapyFebruary 11, 2025 | msn.comINmune Bio price target raised to $23 from $22 at ScotiabankFebruary 11, 2025 | markets.businessinsider.comINmune Bio (NASDAQ:INMB) Price Target Raised to $23.00Scotiabank increased their price target on INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Tuesday.February 11, 2025 | marketbeat.comINmune Bio's CORDStrom shows promise in RDEB treatmentFebruary 10, 2025 | msn.comINmune Bio announces plans to submit FDA BLA for CORDStromFebruary 10, 2025 | markets.businessinsider.comINmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)February 10, 2025 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in JanuaryINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 4,280,000 shares, an increase of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the short-interest ratio is presently 18.6 days.February 4, 2025 | marketbeat.comWhy INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comINmune Bio (NASDAQ:INMB) Rating Increased to Strong-Buy at RODMAN&RENSHAWRODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a report on Tuesday.January 29, 2025 | marketbeat.comINmune Bio expands INKmune trial in prostate cancer to veteransJanuary 28, 2025 | markets.businessinsider.comINmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28, 2025 | markets.businessinsider.comRodman & Renshaw sets INmune Bio stock Buy rating, $23 targetJanuary 28, 2025 | msn.comBTIG maintains INmune Bio stock Buy rating and $21 targetJanuary 28, 2025 | msn.comINmune Bio (NASDAQ:INMB) Now Covered by Analysts at Rodman & RenshawRodman & Renshaw assumed coverage on INmune Bio in a research note on Tuesday. They issued a "buy" rating and a $23.00 price objective on the stock.January 28, 2025 | marketbeat.com Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Media Mentions By Week INMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼0.970.72▲Average Medical News Sentiment INMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼72▲INMB Articles Average Week Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Evolus News Today Replimune Group News Today ArriVent BioPharma News Today Cronos Group News Today Xeris Biopharma News Today Dianthus Therapeutics News Today AnaptysBio News Today KalVista Pharmaceuticals News Today Arbutus Biopharma News Today Trevi Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INMB Stock Free INMB Stock Alerts